Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's shift from commissioning to early utilization at its Galesburg facility. The transition marks a critical phase as Burcon begins to capitalize on its commercial production capabilities across multiple protein platforms.
In fiscal year 2026, Burcon completed commissioning and launched commercial production for Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein. Revenue for the fourth quarter of FY26 reached $0.83 million, up sequentially from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity. The company also set a new production record, with daily output roughly 60% above January through March levels.
The ramp in volume is expected to drive margin improvement through better fixed-cost absorption, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure. Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects spanning pea, canola, and fava applications. Funding to support the Galesburg scale-up includes $6.9 million already completed, with an additional $3.0 million undrawn, and management is targeting $10 million in calendar year 2026 sales.
For more details, view the full announcement here.
